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On the basis that melanomas are of neural crest origin and might contain
somatostatin receptors, the authors utilized II1n Pentetreotide (OctreoScan) to
image 16 melanoma patients with known sites ofdisease. Twelve of 16 patients
were positive with 38 percent imaging all sites. No lesion less than 1.5 cm
imaged nor did one ocular and one amelanotic melanoma. Ofthe five described
somatostatin receptors, OctreoScan binds only 2 and 5 suggesting that not all
melanomas contain those receptors. It is concluded that melanomas contain
somatostatin receptors and that this property might be used for imaging, tumor
suppression with Octreotide, and/or as a target forOctreotide labelled with ther-
apeutic agents such as immune complexes, chemotherapeutic agents or high
energy radioisotopes.
INTRODUCTION
Early in 1995, we hypothesized that malignant melanoma, being of neural crest ori-
gin, might contain somatostatin receptors. If melanomas did contain somatostatin recep-
tors, it should be possible to image them with 1llIn Pentetreotide (OctreoScan) as is the
case with other neuroendocrine tumors such as carcinoids, small-cell carcinoma of the
lung and islet cell tumors of the pancreas. A search of the literature provided one refer-
ence by Hoefhagel et al. [1] that described one melanoma patient with a positive
OctreoScan. A note added in proof stated that six of eight total melanoma patients had
been imaged by OctreoScan.
MATERIALS AND METHODS:
A supply of OctreScan was obtained courtesy of Dr. L.K. Kvols, Mallinckrodt, Inc.,
and 16 successive patients with known metastatic malignant melanoma were imaged.
Patients were seen and selected from the senior author's patients. Ifmalignant melanoma
patients had measurable disease, they were considered for study with OctreoScan.
Measurable disease included shallow, small skin lesions, palpable nodes, or masses found
by other radiologic tests.
Gamma cameras used were Prism 2000XP and Prism 300 (Picker International, two-
and three-headed cameras) and Genesys (ADAC). Planar acquisitions were 10
minutes/image, except some ofthe 48 or 72 hour images were 20 minutes. Single photon
emission computed tomography (SPECT)b imaging was carried out on the Prism cameras,
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using 40 second stops at 6-degree intervals; on some 48 or 72 hour images, the time was
increased to 60 seconds.
Patients were interviewed and given six mCi (222 megaBecquerels) of lllln pente-
treotide intravenously. Most had planarimaging at fourhours at the site ofknown disease,
and all had planar imaging at 24 and 48 hours. A few had additional imaging at 72 hours.
SPECT imaging was carried out of chest (usually at 24 hours), abdomen (usually at 48
hours) or pelvis (usually at 48 hours), or two or three of these areas, depending on
known/suspected site(s) of disease. One patient did not fit within the SPECT gantry, and
only planar imaging was performed.
SPECT images were reconstructed on an Odyssey VP workstation (Picker) using a
ramp pre-filter and a low-pass Butterworth filter of order and cut-off determined by the
appearance of the images. They were re-sliced in orthogonal planes and viewed on a
workstation and printed. They were also used to construct a Max Pixel Raytrace image
viewed on the workstation.
Images were examined by several Nuclear Medicine/Radiology staff. Any other
imaging modalities available were also examined at the time of initial interpretation, and
a clinical report was generated.
Seventeen scans were performed in 16 patients. Ages ranged from 29 to 82 with a
mean of 58 years. There were eight men and eight women. There was one ocular
melanoma, and 15 cutaneous melanoma, of which 14 were melanotic and one was ame-
lanotic.
RESULTS
In four patients, or 25 percent, Octreoscan was completely negative, despite known
disease. In six patients, or 38 percent, some lesions were imaged and some were not. In
the remaining six patients, or 38 percent, all known disease was identified by Octreoscan.
Seventy-five percent ofpatients had at least some lesions identified.
The smallest lesions detected by Octreoscan was a 1.5 cm lung metastasis noted on
computed tomography. Of note in the six patients with known disease partially imaged, a
total ofeight lesions were missed. Four ofthese eight lesions were smaller than 1.5 cm.
In the patient in which a follow-up Octreoscan was obtained one year later, the sec-
ond scan depicted progression ofcutaneous lesions with regression of lung disease.
Ten ofthe imaged patients underwent excision of some or all oftheir tumor, which is
being analyzed for somatostatin receptors by Dr. Sue O'Dorisio at Ohio State University
in Columbus, Ohio. Correlation of results is pending, and it is anticipated we may deter-
mine the receptor makeup of patients whose tumors are imaged by OctreoScan [2].
Several patients with large lesions in the liver or spleen that did not take up OctreoScan
provided definite negative images, which afforded a useful diagnostic image.
DISCUSSION
These data confirm Hoefhagel's observation that some melanomas can be imaged by
OctreoScan, indicating the presence of functional somatostatin receptors. While the per-
centage of positive scans limits the diagnostic utility of Octreoscan in melanoma at pre-
sent, this is a verypreliminary report, and furtherexperience will be required to determine
the true sensitivity and specificity ofthe test when compared to histologic verification of
melanoma.
The finding that some melanomas contain somatostatin receptors confirm that
melanoma is a neuroendocrine tumor and implies some host control ofmelanoma growth.
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Given the paucity ofeffective therapies for melanoma, this is a very exciting observation.
It suggests the possibility of suppressing melanoma growth with somatostatin analogs
such as long-acting Octreotide. Perhaps more importantly, somatostatin receptors provide
a potential target for somatostatin analogs labeled with tumor specific immune complex-
es, chemotherapeutic agents or high-energy radiotherapeutic sources.
The first long-acting somatostatin analog to be developed for clinical use was
octreotide, with a half-life oftwo hours, yet retaining similar physiologic actions. Unlike
somatostatin-14 and -28, which bind to all five somatostatin receptor subtypes with high
affinity, octreotide binds to somatostatin receptor subtypes 2 and 5 with similar affinity as
native somatostatin-14 and -28, but with much lower affinity for somatostatin receptor
subtypes 1, 3 and 4.
Since some melanomas did not image at all with OctreoScan, we can assume that not
all melanomas contain somatostatin receptors 2 or 5. It is ofnote that neitherthe ocular or
the amelanotic melanoma in this series were imaged by OctreoScan. Both ofthese tumors
are aggressive andparticularly resistant to host control or treatment once they have metas-
tasized. Very possibly their receptor content is related to this resistance.
In summary, current potential clinical application of OctreoScan in melanoma
patients appears limited to that subset of patients who have disease expressing somato-
statin receptor 2 or 5. For this group, OctreoScan may be useful in 1) diagnosing disease,
as a potential adjunct to scintigraphy and identification of sentinel lymph nodes in selec-
tive lymph node dissection or as a means to localize early metastatic disease; 2) therapy,
by selectively targeting tumors with high somatostatin receptor subtype 2 or 5 expression
with radionuclide therapy or perhaps in trials of systemic octreotide administration; and
3) follow-up of patients with known somatostatin receptor subtype 2 or 5 disease.
Limitations ofpractical use for OctreScan may be overcome in the future with the devel-
opment of somatostatin analogs that selectively bind the other somatostatin receptor sub-
types 1, 3 and 4.
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